Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · IEX Real-Time Price · USD
6.21
+0.09 (1.47%)
May 2, 2024, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Revenue
In the year 2023, Amneal Pharmaceuticals had annual revenue of $2.39B with 8.20% growth. Revenue in the quarter ending December 31, 2023 was $616.98M with 1.18% year-over-year growth.
Revenue (ttm)
$2.39B
Revenue Growth
+8.20%
P/S Ratio
0.80
Revenue / Employee
$310,858
Employees
7,700
Market Cap
1.92B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
Dec 31, 2015 | 866.28M | 80.66M | 10.27% |
Dec 31, 2014 | 785.62M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
BrightSpring Health Services | 8.83B |
Tilray Brands | 743.25M |
Galapagos NV | 266.36M |
Ginkgo Bioworks Holdings | 251.46M |
Avadel Pharmaceuticals | 27.96M |
Avidity Biosciences | 9.56M |
Fusion Pharmaceuticals | 2.07M |
AMRX News
- 3 days ago - California teams with Amneal Pharma for cheaper, generic version of Narcan - Market Watch
- 8 days ago - Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose - Business Wire
- 16 days ago - Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine - Business Wire
- 22 days ago - Amneal to Report First Quarter 2024 Results on May 3, 2024 - Business Wire
- 5 weeks ago - Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Business Wire
- 5 weeks ago - Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension - Business Wire
- 2 months ago - Amneal Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 - Business Wire